Purpose: Women with unilateral breast cancer are at an increased risk for the development of contralateral breast cancers. In this study, we evaluated the incidence and pathology of contralateral breast cancer detection by preoperative magnetic resonance imaging (MRI) in Taiwanese women with primary operable breast cancer. Methods: A retrospective review of patients who received preoperative breast MRI and underwent operation for breast cancer at single institution between January 2011 and December 2013 was conducted. The incidence, pathology, and management methods of MRI-detected contralateral breast lesions were reported and analyzed. Results: A total of 735 patients enrolled in the current study, and 70 patients (9.5%) were found to have contralateral breast lesions detected by preoperative MRI. Among these 70 patients, 44 (62.9%) received surgical intervention for the MRI-detected contralateral occult lesions. Malignancy was detected in the final pathologic specimen in 21 (47.7%) patients, and benign lesions found in 23 (52.3%) patients. Among these 21 MRI-detected occult contralateral breast cancers, there were 7 (33.3%) invasive ductal carcinoma, 1 (4.8%) mucinous carcinoma, and 13 (61.9%) ductal carcinoma in situ. Compared with the pathology of the 735 primary operable breast cancers, MRI-detected contralateral breast cancer was associated with higher in situ carcinoma (61.9% vs. 15.9%, P < 0.01). The positive predictive value of MRI was 37.7%, eight of 28 MRI Breast Image Reporting and Data System(BI RADS)-4 cases had a pathological malignancy; nine of 17 MRI BI RADS-5 cases had a pathological malignancy. Conclusion: In women with known unilateral breast cancer, 2.9% of patients were diagnosed to have synchronous contralateral breast cancer when combined with preoperative breast MRI evaluation. Adequate biopsy or surgical strategy should be discussed in patients whose preoperative breast MRI showed contralateral occult lesions with suspicious for malignancy.
INTRODUCTION
Breast cancer is the most common type of cancer in women in most Western countries [1] and is the leading cause of cancer death in many Asian countries, [2, 3] including Taiwan. [2, 4] Women with unilateral breast cancer are at an increased risk for the development of contralateral breast cancers, with a 1%-5% incidence of synchronous cancer and a 3%-13% incidence of metachronous cancer. [5] [6] [7] Moreover, women with bilateral breast cancer were found to have worse prognoses than those with unilateral breast cancer. Methods to enhance early detection of synchronous contralateral breast cancer would be important for patients newly diagnosed with breast cancer.
Contrast-enhanced dynamic magnetic resonance imaging (MRI) has been shown to be a useful imaging modality for the diagnosis of breast cancer. [8, 9] MRI of the breast has been shown to be valuable in estimating tumor size [10, 11] and been reported to have high sensitivity in detecting occult breast lesions. [6, 7, 12] Some study reported that breast MRI can detect 3%-5% of occult tumors in the contralateral breast. [5] [6] [7] However, data regarding the diagnostic performance of breast MRI in the evaluation of contralateral synchronous breast cancer detection of Taiwanese women with breast cancer were lacking.
In this study, we evaluated diagnostic performance of breast MRI in the detection of synchronous contralateral breast cancer in Taiwanese women with primary operable breast cancer. The incidence, pathology, and management of patients with MRI-detected contralateral occult breast lesions were analyzed and reported.
METHODS

Patients
A retrospective review of patients who underwent operation for breast cancer from January 2011 to December 2013 was conducted at Changhua Christian Hospital (CCH), a tertiary medical center at Central Taiwan. Patients who diagnosed as primary operable breast cancer, received preoperative evaluation with conventional breast imaging combined with MRI, and received definite breast cancer at CCH were included. Patients who did not receive surgery because of distant metastasis or neoadjuvant chemotherapy were excluded. This study was approved by the Institutional Review Board (IRB) of CCH (CCH IRB No. 140404).
To evaluate the efficacy of preoperative breast MRI for contralateral breast tumor detection and the optimal management strategy of these detected contralateral occult lesions, patients' clinicopathological data and surgical methods were collected. Information recorded from patient charts included patient age, location of tumor, biopsy method, tumor size, lymph node status, tumor stage, tumor grade, estrogen receptor (ER) status, progesterone receptor (PR) status, and HER-2 status. The MRI images and reports were reviewed to identify whether contralateral breast lesions was detected. The subsequent biopsy result and surgical method after preoperative MRI study were reviewed. The data collection was performed by special trained study nurse (YLL) and verified by main principle investigator (HWL).
Diagnostic imaging equipment/conventional breast imaging
Patients enrolled in the current study were primary operable breast cancer patients, who had received preoperative conventional breast imaging with mammography and sonography. Standard mediolateral oblique and craniocaudal views of mammograms were obtained for all patients. Ultrasound procedures were performed with the patient in the supine position. Imaging was performed with a high-resolution 5-12 MHz linear array transducer, including color Doppler ultrasonography (Voluson 530D and 730D, Kretz Technik, Zipf, Austria). The sonography examinations were carried out by experienced, board-certified breast physicians.
Magnetic resonance imaging of study
The MRI protocol used in the current study was reported in previous studies [11, 13, 14] and summarized. MRI was performed with a Siemens (Verio) 3.0 Tesla magnet. All patients were imaged in the prone position with both breasts placed into a dedicated 16 channel breast coil. MRI protocols included bilateral axial turbo-spin-echo fat-suppressed T2-weighted image (retention time [TR]/echo time [TE] 4630/70 ms; field of view 320 mm; slice thickness 3 mm; number of excitations 1), axial turbo-spin-echo T1-weighted image (TR/TE 736/9.1 ms; field of view 320 mm; slice thickness 3 mm; number of excitations 1), diffusion-weighted images (TR/TE 5800/82 ms; field of view 360 mm; slice thickness 3 mm, with b values of 0, 400, and 800 sec/mm2) and measuring the ADC value.
Dynamic MRI using a three-dimensional fat-suppressed volumetric interpolated breath-hold examination sequence with parallel acquisition was obtained before and five times after the bolus injection of gadobenate dimeglumine (0.1 mmol/kg). Both breasts were examined in the transverse plane, with 60 s interval of each phase dynamic images. The dynamic MRI parameters were as follows: TR/TE 4.36/1.58 ms; field of view 320 mm; slice thickness 1 mm.
The interpretation principle for measurement of tumor size by MRI was based on using a commercially available MRI computer-aid diagnosis (CAD) system with computer-based tumor segmentation in volume rendering data set by DynaCAD Version 2.1 for Breast MRI (In vivo, Gainesville, FL, USA). For avoiding under estimate the tumor volume due to blooming effect and early periductal enhancement, the result was manipulated by experienced radiologist after computer-based tumor segmentation. The whole-breast MRI readings were carried out by experienced, board-certified breast radiologist (HKW).
All the breast imagings, including mammography, sonography, and MRI, were recorded according to the Breast Image Reporting and Data System (BI-RADS). [15] 
Statistical analyses
Data are expressed as mean ± standard deviation for continuous variables. Independent t tests were used for the comparison of continuous variables. Categorical variables were normally tested by the χ 2 -test when appropriate.
All P values are two-tailed; a P < 0.05 was considered to indicate statistical significance. All statistical analyses were performed with SPSS 19.0 software (IBM, Armonk, NY, USA).
Ethical approval
The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of the institute. Informed written consent was obtained from all patients prior to their enrollment in this study.
RESULTS
According to the inclusion and exclusion criteria, a total of 735 Taiwanese women with primary operable breast cancer patients who received preoperative breast MRI and surgical treatment during January 2011 to December 2013 were selected from CCH Breast Cancer Database. The mean age of them was 52.7 ± 10.7 years, and mean tumor size 2.3 ± 1.6 cm. Most of them were early-stage breast cancer, with stage 0 (15.9%), stage I (32.7%), stage II (41.1%), stage III (9.9%), and stage IV (0.4%). The clinicopathological characteristics of these 735 patients are summarized in Table 1 .
Among the 735 primary operable breast cancer patients, 70 patients (9.5%) were found to have contralateral breast lesions detected by breast MRI. Thirty-nine (55.7%) patients underwent preoperative biopsy for the MRI-detected contralateral lesion before surgery. Seventeen patients received core needle biopsy with second-look ultrasound, Table 2 .
Twenty-one (2.9%) out of 735 patients were diagnosed to have synchronous contralateral breast cancer when combined with preoperative breast MRI evaluation. Compared with the pathology of the 735 primary operable breast cancers, MRI-detected synchronous contralateral breast cancers were associated with higher incidence of in situ carcinoma (61.9% vs. 15.9%, P < 0.01). Figure 2 showed examples of patients diagnosed with synchronous contralateral breast cancer who received bilateral breast conserving surgeries or bilateral nipple sparing mastectomy with immediate breast reconstruction.
DISCUSSION
To evaluate the efficacy of breast MRI in the detection of synchronous contralateral breast cancer, we enrolled 735 primary operable breast cancer patients with preoperative breast MRI and received surgery in single institution. MRI detected 70 (9.5%) synchronous contralateral lesions in 735 patients, and 21 (30%) of them were proved to be malignancy. Compared with the pathology of the 735 primary operable breast cancers, MRI-detected contralateral breast cancers were associated with higher in situ carcinoma rate (61.9% vs. 15.9%, P < 0.01). These findings supported that breast MRI is a highly sensitive imaging tool, which is useful for preoperative evaluation of breast cancer.
In the current study, we found that, with the adding of breast MRI to conventional imaging studies, synchronous contralateral breast cancer was 2.9% (21/735), which was similar to previous literature reported 3%-5% synchronous breast cancer rate in Western countries. [5] [6] [7] Compared to our previous study cohort, [13] which had 1.1% (8/733) synchronous contralateral breast cancer rate in patients received conventional breast imaging (mammography and sonography) alone, combined breast MRI had superior synchronous contralateral breast cancer detection rate (2.9% vs. 1.1%, P < 0.01). Moreover, one could speculate that adding breast MRI would increase about 1.8% of synchronous contralateral breast cancer detection rate than using conventional breast imaging alone.
In Houssami's study [16] for the evaluation of the contralateral breast cancer detection by preoperative MRI, the incidence of suspicious MRI findings was estimated to be 9.3%, with a PPV of 48% and a false positive rate of 52%. In our current study, MRI detected 70 (9.5%) contralateral lesions in 735 patients, and 21 of them were proved to be malignancy. The PPV of the RI-detected contralateral lesion in our study was therefore 37.7%, which is compatible to other reports.
The detection of additional abnormal enhancing lesions in breast MRI might be "problematic" for subsequent patient management. The false positive rate for the additional lesion is high as observed in our current study; around 70% of the so-called "occult contralateral breast lesion" would prove to be benign neoplasms after surgical excision [ Figure 1 ]. As shown in Table 2 , 52.3% of the 44 surgical excised suspicious lesions were found to be benign neoplasms, and most of them were fibroadenomas (34.5%) and fibrocystic change (43.5%).
Sometimes, it is confusing whether these lesions should be ignored, followed up, or referred for biopsy. [5] [6] [7] In addition, the image-guided biopsy before surgery is increasing when breast MRI was incorporated in the preoperative evaluation. [5, 6] As showed in our Figure 1 , 39 of the 70 patients with MRI-detected occult synchronous contralateral lesions received preoperative biopsy. Biopsy results of proliferative lesion-like papilloma or atypia of the synchronous contralateral lesions were suggested to be excised at the same time when primary breast cancer operation is performed. As one of our patients had papilloma core needle biopsy for the contralateral breast lesion, ductal carcinoma in situ arising from papilloma was diagnosed in the final lumpectomy specimen.
Our study was limited due to its retrospective nature and possible selection bias. Patients with contralateral occult lesions detected by MRI did not receive surgical excision in every case to confirm the nature of the lesion. This might, therefore, underestimate the actual synchronous breast cancer rate or increase the false positive rate of breast MRI. Furthermore, we did not provide how many cases of contralateral malignancy could be detected by conventional breast imaging alone in the enrolled 735 patients. We did not clearly demonstrate that the adding of breast MRI would result in how many additional synchronous contralateral cancer cases being diagnosed. The 1.8% increase for detection of synchronous contralateral breast cancer detection was a rough estimation based on two different patients' cohort. However, we did collected 735 primary operable breast cancer patients with preoperative breast MRI and received surgical intervention at single institution with detailed pathologic report, which enable us to complete the current study. The result obtained from our study could reflect the synchronous breast cancer rate of Taiwanese women with breast cancer was 2.9%, which was higher than expected from previous reported series, [17] which did not include breast MRI as preoperative imaging evaluation.
CONCLUSION
The risk of synchronous contralateral breast cancer, 2.9% incidence in the current study, should be kept in mind for preoperative evaluation of primary operable breast cancer patients. Biopsy procedure for tissue diagnosis or surgical strategy discussed with patients is warranted if suspicious synchronous contralateral lesion been detected by conventional imaging or breast MRI.
